Structure Therapeutics Inc. Sponsored ADR $GPCR Position Lessened by Eversept Partners LP

Eversept Partners LP trimmed its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 23.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,561 shares of the company’s stock after selling 38,830 shares during the period. Eversept Partners LP owned about 0.21% of Structure Therapeutics worth $8,872,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. CWM LLC raised its holdings in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Structure Therapeutics by 530.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the last quarter. State of Wyoming acquired a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Structure Therapeutics during the 4th quarter valued at about $127,000. Finally, Banque Cantonale Vaudoise acquired a new stake in shares of Structure Therapeutics during the 4th quarter valued at about $205,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $45.00 on Thursday. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The company’s fifty day moving average price is $43.09 and its two-hundred day moving average price is $57.53.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, sell-side analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. HC Wainwright reduced their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Finally, Citizens Jmp lowered their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.